Carisma Therapeutics Inc (CARM) Cours

Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company's macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company's lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company's second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more